Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Modality Therapy for Primary CNS Lymphoma
NCT00003929Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jun 1998
- Primary completion
- Mar 2000
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of filgrastim in primary central nervous system lymphoma (PCNSL), sponsored by Case Comprehensive Cancer Center. Planned start Jun 1998; status: withdrawn.
02
Drugs
filgrastim
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00003929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003929.